A new method for detecting T cell function
By establishing a dual signaling model of TCR stimulation and CD28 costimulation, combining gene transfection and flow cytometry, the unreliability problem of existing T cell function detection is solved, and accurate detection of T cell activation and Treg function is achieved. It provides theoretical basis and experimental new data for early autoimmune disease diagnosis.
Patent Information
- Application Number
- CN202111284669.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-11-01
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2041-11-01
AI Technical Summary
The existing T cell function detection methods are not reliable, difficult to quantify and have no specificity, and cannot accurately evaluate the status and properties of T cell activation, especially in diagnosing autoimmune responses and diseases.
Using a dual signal model of TCR stimulation and CD28 costimulation, expression of CD80 or CD86 through gene transfection, combined with flow cytometry and antibody bead sorting, Treg inhibition and CTLA-4 transend-endocytosis models were established, and laser confocal microscopy was used. Quantitative detection was carried out in ABC magnetic bead staining to distinguish the dependence of naive and memory T cells on co-stimulation, and the negative regulatory effect of Treg on T cell activation was studied.
Accurate detection of T cell activation status and Treg function, provides theoretical basis and experimental new data for early diagnosis of autoimmune diseases, improves the reliability and specificity of the detection, and can analyze non-CD28-dependent T cell activation and Treg Immune regulation function is abnormal.
Smart Images

Figure CN113981031B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of medical detection, and in particular relates to a novel T cell function detection method. Background Art
[0002] Immune cell phenotype (such as CD80, CD86, CD28, CTLA-4, etc.) is the basis for judging the function of immune cells. Traditional immune cell phenotype detection is to determine the expression level of a protein by quantitatively identifying the MFI value of fluorescent antibodies against a certain protein through flow cytometry (FACS). However, this method is unreliable and insufficiently quantitative due to the daily fluctuations in instrument settings (such as laser beam energy).
[0003] The existing T cell activation test still uses the original PBMC as the activation object. Although this method is fast and simple, it is very inaccurate. Because there are multiple APC subtypes in PBMC (such as DC, monocytes, B cells) that can co-stimulate T cell activation, and the proportion of each APC subtype, the expression of co-stimulatory ligands (CD80, CD86) and HLA matching in the population are also different, these multiple factors make the PBMC activation test unable to specifically indicate the path and nature of T cell activation, and therefore cannot be compared with the population; there are various T cell subtypes in PBMC such as initial (naive) T cells (nT cells), memory (memory) T cells (mT cells), conventional (conventional) T cells (cT cells), regulatory (regulatory) T cells (Treg cells), and the interaction between them makes it impossible for PBMC activation to accurately evaluate the true activation state and degree of each T cell itself.
[0004] The traditional method of T cell activation is to use CD3+CD28+antibody magnetic beads to provide the primary and co-stimulatory signals required for regulating T cell activation and expansion. Although this method can activate CD28, it cannot distinguish the difference between the two ligands of CD28 (CD80 and CD86). In the current system of CD80, CD86 dual ligands and CD28, CTLA-4 dual receptors, the functional differences between CD80 and CD86 need to be further explored, so it is obviously not advisable to activate CD28 with CD28 antibodies.
[0005] Under normal circumstances, autoimmune response T cells are in an inactive state, but if the Treg regulatory function itself is impaired, it can also lead to abnormal activation of such T cells, indirectly inducing autoimmune reactions and diseases. However, clinical testing of Treg immune regulatory function is still blank, so further testing of the molecular mechanism of Treg regulatory effect is out of the question.
[0006] In summary, the latest research results and inferences indicate that the diagnosis of human autoimmune reactions and diseases must start with the activation and regulation mechanisms of autoimmune T cells.
[0007] However, the current clinical T cell function tests are not reliable enough, difficult to quantify and non-specific, and urgently need to be updated, improved and supplemented. Summary of the invention
[0008] The present invention provides a novel T cell function detection method, aiming to solve the problems existing in the prior art. The present invention is implemented as follows: a novel T cell function detection method comprises the following steps:
[0009] S1: After blood samples were collected from patients with type 1 diabetes, rheumatoid arthritis, and healthy controls and appropriately grouped, a dual-signal model of T cell activation using TCR stimulation and CD28 co-stimulation was first created;
[0010] S2: After gene transfection to express the co-stimulatory molecule CD80 or CD86, flow cytometry was used to quantitatively measure and compare the relationship between CD80 and CD86 co-stimulation and T cell activation, and antibody magnetic bead sorting was used to distinguish the dependence of naive and memory T cells on co-stimulation;
[0011] S3: Establish Treg suppression and CTLA-4 transcytosis models and perform laser confocal microscopy to study the negative regulatory effects of Treg on T cell activation;
[0012] S4: Specific markers on immune cells are detected by methods such as ABC magnetic bead staining, and quantitative and controllable T cell activation and Treg function tests are performed to detect whether T cell activation is abnormal.
[0013] Furthermore, the T cell detection steps of S4 are as follows:
[0014] S401: Quantification of protein expression by flow cytometry staining with fluorescent ABC magnetic beads;
[0015] S402: magnetic bead sorting and purification of T cell subsets;
[0016] S403: T cell co-stimulation test without antigen;
[0017] S404: T cell antigen co-stimulation test;
[0018] S405: Treg negative immune regulation test;
[0019] S406: T cell transcytosis assay.
[0020] Further, S401 includes the following steps:
[0021] S4011: perform fluorescent antibody FACS labeling of ABC surface secondary antibody and fluorescent antibody FACS labeling of cell GFP fusion protein respectively;
[0022] S4012: After FACS labeling of the ABC surface secondary antibody with the fluorescent antibody, a standard curve between the number of ABC bead surface secondary antibodies and the MFI of the fluorescent antibody was established; after FACS labeling of the cell GFP fusion protein with the fluorescent antibody, a standard curve between the MFI of the cell GFP fusion protein and the MFI of the fluorescent antibody was established;
[0023] S4013: After the above two standard curves are established, a standard curve of the MFI of the ABC bead surface and cell GFP fusion protein is established;
[0024] S4014: Derive the calculation formula for the number of protein molecules and the MFI of cell surface GFP fusion protein.
[0025] Further, S403 includes the following steps:
[0026] S4031: CD11c+ dendritic cells were added with CTLA-4Ig co-stimulatory receptor inhibitor, Violet fluorescently labeled T cells were added with free anti-CD3TCR stimulatory antibody, and immunoregulatory T cells were added with free anti-CTLA-4 inhibitory antibody;
[0027] S4032: The three types of cells mentioned above were cultured at a constant temperature for 5 days, during which cell counting beads were added;
[0028] S4033: FACS detection of T cell division and cell counting;
[0029] S4034: Analysis of inhibition of T cell division and its relationship with CTLA-4.
[0030] Further, S404 includes the following steps:
[0031] S4041: CHO-CD80vsCD86GFP cells were added with CTLA-4Ig co-stimulatory receptor inhibitor, and Violet fluorescently labeled T cells were added with free anti-CD3TCR stimulatory antibody;
[0032] S4042: The above two cells were cultured at a constant temperature for 5 days, during which time cell counting beads were added;
[0033] S4043: FACS detection of T cell division and cell counting;
[0034] S4044: Analyze and compare the kinetics of CD80 vs CD86 co-stimulation of T cell division.
[0035] Further, S405 includes the following steps:
[0036] S4051: CHO-HLA-DR4+CD80vsCD86GFP cells were added with CTLA-4Ig co-stimulatory receptor inhibitor, and Violet fluorescently labeled T cells were added with free TCR to stimulate immune superantigen TSST-1;
[0037] S4052: The above two cells were cultured at a constant temperature for 5 days;
[0038] S4053: TCR-Vβ2 is labeled with a fluorescent specific antibody, during which cell counting beads are added;
[0039] S4054: FACS detection of T cell division and cell counting;
[0040] S4055: Analyze and compare the kinetics of CD80 vs CD86 co-stimulation of T cell division.
[0041] Further, S406 includes the following steps:
[0042] S4061: CD4+T cells added with free anti-CD3TCR stimulating antibody and CHO-CD80GFP cells;
[0043] S4062: FACS detection of GFP capture by T cells and fluorescence microscopy analysis of GFP phagocytosis by T cells.
[0044] Compared with the prior art, the beneficial effects of the present invention are as follows: a novel T cell function detection method of the present invention, based on the previous studies revealing that the T cell activation threshold and functional changes are meaningful for the discovery of autoimmune diseases, proposes to establish a set of novel T cell function detection methods for the early diagnosis of autoimmune diseases, aiming to establish a new detection method based on TCR sensitivity and T cell activation threshold, to analyze the diagnostic significance of non-CD28-dependent T cell activation and abnormal Treg immune regulation function for autoimmune diseases, and to provide a theoretical basis and new experimental data for the early diagnosis of the disease. BRIEF DESCRIPTION OF THE DRAWINGS
[0045] Figure 1 This is a flow chart of quantitative examination of protein expression by flow cytometry staining fluorescent ABC magnetic beads of the present invention;
[0046] Figure 2 This is a flow chart of the magnetic bead sorting and purification of T cell subsets of the present invention;
[0047] Figure 3 This is a flow chart of the T cell antigen-free co-stimulation test of the present invention;
[0048] Figure 4This is a flow chart of the T cell antigen co-stimulation test of the present invention;
[0049] Figure 5 This is a flow chart of the Treg negative immune regulation test of the present invention;
[0050] Figure 6 This is a flow chart of the T cell transcytosis assay of the present invention;
[0051] Figure 7 It is a schematic diagram of the inhibitory effect of CD86 co-stimulation and CTLA-4 on CD86 transcytosis on T cell activation in the present invention;
[0052] Figure 8 It is a schematic diagram of the loss of CTLA-4 protein expression and dysfunction on regulatory T cells in the blood of patients with CTLA-4 gene mutations of the present invention;
[0053] Fig. 9 This is a schematic diagram showing that the CTLA-4 protein expression on regulatory T cells in the blood of immunodeficient patients of the present invention is normal but functionally impaired. DETAILED DESCRIPTION
[0054] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.
[0055] 1. Preliminary experimental results obtained by the research team:
[0056] ① This experimental group has created a dual-signal model of T cells to analyze the dynamic changes in the level of CD28 co-stimulatory signals on T cell proliferation under specific TCR stimulation signals, as well as the inhibitory rule of CTLA-4 regulating CD86 levels on T cell proliferation in T cell activation dependent on CD28 co-stimulatory signals. This has preliminarily determined the detection indicators and experimental methods in the experiment of studying the regulation of CTLA-4 on CD28 co-stimulatory signals.
[0057] See also Figure 7 (A) CD86 transcytosis can be blocked by antibodies against CTLA-4
[0058] (B) Loss of CD86 on cells expressing CD86 synergizes with CD86 capture in cells expressing CTLA-4. (C, D, and E) Transcytosis of CD86 by CTLA-4 is proportional to the amount of CD86 protein expressed and the duration of co-culture.
[0059] (F, G, and H) The number of CD86 molecules remaining on cells expressing CD86 is inversely proportional to the amount of CD86 captured on cells expressing CTLA-4.
[0060] ②At the same time, these experimental methods and technologies were used to conduct pioneering clinical research. The research team has completed the detection of 20 carriers of congenital genetic immune regulation gene defects, including 12 patients with autoimmune diseases who completed the CD3+CD4+CD25+FOXP3+CTLA-4+ regulatory T cell phenotype and functional status detection. It was found that the number and quality of regulatory T cells expressing CTLA-4 in the blood of patients were significantly lower than those in the healthy control group ( Figure 8 , Fig. 9 ) tested in a dual-signal experimental model that CTLA-4 on Tregs regulates its effect on the co-stimulatory signal of CD28 by transcytosing CD80 or CD86 on antigen-presenting cells (APCs) to achieve inhibition of T cell activation, which was a successful preliminary verification of the existing experimental basis.
[0061] See also Figure 8 , (A). The total expression of CTLA-4 protein receptors with gene mutations expressed in regulatory T cells decreased
[0062] (B). The mechanism of transcytosis of CD80-GFP ligand by CTLA-4 receptors induced by genetic mutations in regulatory T cells is reduced.
[0063] (C). The mutant CTLA-4 protein receptor transfected in CHO cells has reduced ability to phagocytose free CD80-Ig ligand.
[0064] (D). Negative regulatory T cells (Treg) suppressive dysfunction with mutant CTLA-4 protein receptors.
[0065] See also Fig. 9 , (A). The total expression of CTLA-4 protein receptors with gene mutations expressed in regulatory T cells was normal
[0066] (B). The mechanism of CTLA-4 protein receptor phagocytosis of free CD80-Ig ligand is reduced in CTLA-4 protein receptors with CTLA-4 gene mutations in regulatory T cells.
[0067] 2. Please refer to Figure 1-6 The present invention provides a novel T cell function detection method, comprising the following steps:
[0068] Step 1: After collecting blood samples from patients with type 1 diabetes, rheumatoid arthritis, and healthy controls and appropriately grouping them, a dual-signal model of T cell activation using TCR stimulation and CD28 co-stimulation was first created;
[0069] Step 2: After gene transfection to express the co-stimulatory molecule CD80 or CD86, flow cytometry was used to quantitatively measure and compare the relationship between CD80 and CD86 co-stimulation and T cell activation, and antibody magnetic bead sorting was used to distinguish the dependence of naive and memory T cells on co-stimulation;
[0070] Step 3: Establish Treg suppression and CTLA-4 transcytosis models and perform laser confocal microscopy to study the negative regulatory effect of Treg on T cell activation;
[0071] Step 4: Detect specific markers on immune cells through methods such as ABC magnetic bead staining, and conduct quantitative and controllable T cell activation and Treg function tests to detect whether T cell activation is abnormal.
[0072] The present invention is applicable to people with congenital hereditary and acquired immune gene or protein functional defects. The T cell detection process is as follows:
[0073] 1. Quantification of protein expression by flow cytometry staining with fluorescent ABC magnetic beads, the process is as follows Figure 1 .
[0074] 1.1 Perform fluorescent antibody FACS labeling of ABC surface secondary antibody and cell GFP fusion protein respectively;
[0075] 1.2 After the fluorescent antibody FACS labeling of the ABC surface secondary antibody, a standard curve between the number of ABC bead surface secondary antibodies and the MFI of the fluorescent antibody was established. After the fluorescent antibody FACS labeling of the cell GFP fusion protein, a standard curve between the MFI of the cell GFP fusion protein and the MFI of the fluorescent antibody was established.
[0076] 1.3 After the above two standard curves are established, the standard curve of MFI of ABC bead surface and cell GFP fusion protein is established;
[0077] 1.4 Derive the calculation formula of protein molecule quantity and cell surface GFP fusion protein MFI.
[0078] 2. T cell subset magnetic bead sorting and purification, the process is as follows Figure 2 .
[0079] 3. T cell antigen-free co-stimulation test, the process is as follows Figure 3 .
[0080] 3.1 CTLA-4Ig co-stimulatory receptor inhibitor was added to CD11c+ dendritic cells, free anti-CD3TCR stimulatory antibody was added to Violet fluorescently labeled T cells, and free anti-CTLA-4 inhibitory antibody was added to immunoregulatory T cells;
[0081] 3.2 The three cells were cultured at a constant temperature for 5 days, during which time cell counting beads were added;
[0082] 3.3FACS detection of T cell division and cell counting;
[0083] 3.4 Analysis of the inhibition of T cell division and its relationship with CTLA-4.
[0084] 4. T cell antigen co-stimulation test, the process is as follows Figure 4 .
[0085] 4.1 CTLA-4Ig co-stimulatory receptor inhibitor was added to CHO-CD80vsCD86GFP cells, and free anti-CD3TCR stimulating antibody was added to Violet fluorescently labeled T cells;
[0086] 4.2 The above two cells were cultured at a constant temperature for 5 days, during which time cell counting beads were added;
[0087] 4.3FACS detection of T cell division and cell counting;
[0088] 4.4 Analyze and compare the kinetic relationship between CD80 vs CD86 co-stimulation of T cell division.
[0089] 5. Treg negative immune regulation test, the process is as follows Figure 5 .
[0090] 5.1 CHO-HLA-DR4+CD80vsCD86GFP cells were added with CTLA-4Ig co-stimulatory receptor inhibitor, and Violet fluorescently labeled T cells were added with free TCR to stimulate immune superantigen TSST-1;
[0091] 5.2 The above two cells were cultured at a constant temperature for 5 days;
[0092] 5.3 TCR-Vβ2 is labeled with fluorescent specific antibodies, and cell counting beads are added during this period;
[0093] 5.4FACS detection of T cell division and cell counting;
[0094] 5.5 Analyze and compare the kinetic relationship between CD80 vs CD86 co-stimulation of T cell division.
[0095] 6. T cell transcytosis test, the process is as follows Figure 6 .
[0096] 6.1CD4+T cells were added with free anti-CD3TCR stimulating antibody and CHO-CD80GFP cells;
[0097] 6.2 FACS was used to detect GFP capture by T cells, and fluorescence microscopy was used to analyze GFP phagocytosis by T cells.
[0098] The following are the advantages of the present invention compared with the traditional T cell function detection method:
[0099] (1) Quantitative analysis of new markers and establishment of a database: Immune cell phenotype (such as CD80, CD86, CD28, CTLA-4, etc.) is the basis for judging the function of immune cells. Traditional immune cell phenotype detection is to determine the expression level of a protein by quantitatively identifying the MFI value of a fluorescent antibody against a certain protein through flow cytometry (FACS). However, this method is unreliable and not quantitative enough due to the daily fluctuations in instrument settings (such as laser beam energy). If a new method of antibody binding capacity (ABC) magnetic bead staining combined with flow cytometry is used, it will not be affected by the machine and can accurately calculate the number of protein molecules. This will greatly improve the reliability and accuracy of phenotypic examinations, and at the same time, a database for large sample analysis can be established to provide a baseline for the expression of various proteins for population comparison.
[0100] (2) Replace whole peripheral blood mononuclear cell (PBMC) activation with refined T cell subtype activation detection: Existing T cell activation tests still use original PBMC as the activation object. Although this method is fast and simple, it is very inaccurate. Because there are multiple APC subtypes in PBMC (such as DC, monocytes, B cells) that can co-stimulate T cell activation, and the proportion of each APC subtype, the expression of co-stimulatory ligands (CD80, CD86) and HLA matching in the population are also different, these multiple factors make PBMC activation tests unable to specifically indicate the path and nature of T cell activation, and therefore cannot be compared between populations; there are various T cell subtypes in PBMC such as initial (naive) T cells (nT cells), memory (memory) T cells (mT cells), conventional (conventional) T cells (cT cells), regulatory (regulatory) T cells (Treg cells), and the interaction between the above cells makes it impossible to accurately evaluate the true activation state and degree of each T cell itself through PBMC activation. Therefore, it is necessary to replace PBMC activation and perform activation assays with isolated and purified individual APCs and T cell subsets; by comparison, it is easier to identify pathogenic T cell subsets and perform more targeted testing.
[0101] (3) Create a new dual-signal T cell activation model: The traditional method of T cell activation is to use CD3+CD28+antibody magnetic beads to provide primary and co-stimulatory signals required for regulating T cell activation and expansion. Although this method can activate CD28, it cannot distinguish the difference between the two ligands of CD28 (CD80 and CD86). In the current system of CD80, CD86 dual ligands and CD28, CTLA-4 dual receptors, the functional differences between CD80 and CD86 need to be further explored. Therefore, it is obviously not advisable to activate CD28 with CD28 antibodies. The use of CD28 ligands CD80 or CD86 is more in line with physiological reality and helps to discover the functional differences between CD80 and CD86 in the human population and their value in T cell activation and regulation.
[0102] (4) Create a new T cell regulation and control model: Under normal circumstances, autoimmune response T cells are in an inactive state, but if the Treg regulatory function itself is impaired, it can also lead to abnormal activation of such T cells, indirectly inducing autoimmune reactions and diseases. However, the test of Treg immune regulation function is still blank in clinical practice, so that further testing of the molecular mechanism of Treg regulation is out of the question. The present invention uses a laser confocal microscope and flow cytometer to establish a new DC-mediated Treg inhibition of naive T cells and CTLA-4 transcytosis test model to study the control effect of Treg negative regulation on T cell activation. It will be beneficial to study the functional pairing relationship between CD80, CD86, CD28, and CTLA-4, filling the gap in the lack of functional detection.
[0103] The objects of the present invention are:
[0104] 1. Checkpoint gene sequencing for exempted persons and their family members (if the person being tested is positive): whether there are primary gene mutations in CTLA-4 and PD-1 (i.e. positive).
[0105] 2. Detect the sensitivity of T cell activation in the subject's blood to TCR stimulation and its dependence on CD28 co-stimulation. Further analyze the correlation between this CD28 dependence and subsequent negative regulation of T cells mainly based on CTLA-4.
[0106] 3. Analyze the differences between the subjects' co-stimulatory ligands CD80 and CD86 in setting the threshold for CD28-dependent T cell activation, and study the dynamic relationship between the number of these two co-stimulatory ligand proteins and the differentiation of activated T cells.
[0107] 4. Analyze and compare the expression changes of functional characteristic proteins of T cells activated by CD80 and CD86. Further explore the correlation between phenotype and function. Clarify the functional pairing relationship and mechanism of the two co-stimulatory ligands CD80 and CD86 and the two co-stimulatory receptors CD28 and CTLA-4.
[0108] 5. Use a new method of APC-free Treg in vitro regulation (or inhibition) to test and analyze the negative regulatory function of Tregs in the subjects, dominated by CTLA-4.
[0109] In summary, the novel T cell function detection method proposed in the present invention, based on the previous studies revealing that the T cell activation threshold and functional changes are meaningful for the discovery of autoimmune diseases, proposes to establish a set of novel T cell function detection methods for the early diagnosis of autoimmune diseases, aiming to establish a new detection method based on TCR sensitivity and T cell activation threshold, to analyze the diagnostic significance of non-CD28-dependent T cell activation and abnormal Treg immune regulation function for autoimmune diseases, and to provide a theoretical basis and new experimental data for the early diagnosis of the disease.
[0110] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A method for detecting T cell function for non-diagnostic purposes, characterized in that: include: S1: After blood samples from patients with type 1 diabetes, rheumatoid arthritis, and healthy controls were collected and appropriately grouped, a dual-signal model of T cell activation using TCR stimulation and CD28 co-stimulation was first created; S2: After gene transfection to express the co-stimulatory molecule CD80 or CD86, flow cytometry was used to quantitatively measure and compare the relationship between CD80 and CD86 co-stimulation and T cell activation, and antibody magnetic bead sorting was used to distinguish the dependence of naive and memory T cells on co-stimulation; S3: Establish Treg suppression and CTLA-4 transcytosis models and perform laser confocal microscopy to study the negative regulatory effects of Treg on T cell activation; S4: Detect specific markers on immune cells by methods such as ABC magnetic bead staining, and conduct quantitative and controllable T cell activation and Treg function tests to detect whether T cell activation is abnormal; The steps for S4 T cell detection are as follows: S401: Quantification of protein expression by flow cytometry staining with fluorescent ABC magnetic beads; S402: magnetic bead sorting and purification of T cell subsets; S403: T cell co-stimulation test without antigen; S404: T cell antigen co-stimulation test; S405: Treg negative immune regulation test; S406: T cell transcytosis assay.
2. A T cell function detection method for non-diagnostic purposes according to claim 1, characterized in that: S401 includes the following steps: S4011: perform fluorescent antibody FACS labeling of ABC surface secondary antibody and fluorescent antibody FACS labeling of cell GFP fusion protein respectively; S4012: After FACS labeling of the ABC surface secondary antibody with the fluorescent antibody, a standard curve between the number of ABC bead surface secondary antibodies and the MFI of the fluorescent antibody was established; after FACS labeling of the cell GFP fusion protein with the fluorescent antibody, a standard curve between the MFI of the cell GFP fusion protein and the MFI of the fluorescent antibody was established; S4013: After the above two standard curves are established, a standard curve of the MFI of the ABC bead surface and cell GFP fusion protein is established; S4014: Derive the calculation formula for the number of protein molecules and the MFI of cell surface GFP fusion protein.
3. A T cell function detection method for non-diagnostic purposes according to claim 1, characterized in that: S403 includes the following steps: S4031: CD11c+ dendritic cells were added with CTLA-4Ig co-stimulatory receptor inhibitor, Violet fluorescently labeled T cells were added with free anti-CD3TCR stimulatory antibody, and immunoregulatory T cells were added with free anti-CTLA-4 inhibitory antibody; S4032: The three types of cells mentioned above were cultured at a constant temperature for 5 days, during which cell counting beads were added; S4033: FACS detection of T cell division and cell counting; S4034: Analysis of inhibition of T cell division and its relationship with CTLA-4.
4. A T cell function detection method for non-diagnostic purposes according to claim 1, characterized in that: S404 includes the following steps: S4041: CHO-CD80vsCD86GFP cells were added with CTLA-4Ig co-stimulatory receptor inhibitor, and Violet fluorescently labeled T cells were added with free anti-CD3TCR stimulatory antibody; S4042: The above two cells were cultured at a constant temperature for 5 days, during which time cell counting beads were added; S4043: FACS detection of T cell division and cell counting; S4044: Analyze and compare the kinetics of CD80 vs CD86 co-stimulation of T cell division.
5. A T cell function detection method for non-diagnostic purposes according to claim 1, characterized in that: S405 includes the following steps: S4051: CHO-HLA-DR4+CD80vsCD86GFP cells were added with CTLA-4Ig co-stimulatory receptor inhibitor, and Violet fluorescently labeled T cells were added with free TCR to stimulate immune superantigen TSST-1; S4052: The above two cells were cultured at a constant temperature for 5 days; S4053: TCR-Vβ2 is labeled with a fluorescent specific antibody, during which cell counting beads are added; S4054: FACS detection of T cell division and cell counting; S4055: Analyze and compare the kinetics of CD80 vs CD86 co-stimulation of T cell division.
6. A T cell function detection method for non-diagnostic purposes according to claim 1, characterized in that: S406 includes the following steps: S4061: CD4+T cells added with free anti-CD3TCR stimulating antibody and CHO-CD80GFP cells; S4062: FACS detection of GFP capture by T cells and fluorescence microscopy analysis of GFP phagocytosis by T cells.
